|Dr. Pascal Touchon D.V.M.||Pres, CEO & Director||1.11M||N/A||1963|
|Mr. Utpal Koppikar M.B.A.||Exec. VP & CFO||676.39k||N/A||1971|
|Mr. K. Amar Murugan||Sr. VP & Gen. Counsel||611.76k||N/A||1975|
|Dr. Kristin Yarema Ph.D.||SVP & Chief Commercial Officer||691.41k||N/A||1971|
|Dr. Jakob Dupont M.D.||Exec. VP and Global Head of R&D||885.05k||75.94k||1965|
|Ms. Charlene Banard||Chief Technical Officer||N/A||N/A||1963|
|Dr. Anhco Nguyen||Chief Scientific Officer||N/A||N/A||1973|
|Eric Hyllengren||VP of Investor Relations & Fin.||N/A||N/A||N/A|
|Kerry Beth Daly||Head of Corp. Communications||N/A||N/A||N/A|
|Ms. Amie Krause||Chief People Officer||N/A||N/A||N/A|
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Atara Biotherapeutics, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 7. The pillar scores are Audit: 4; Board: 7; Shareholder Rights: 8; Compensation: 8.